Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ATP4A | P20648 | 1/20 | 0.30 |
| ▸ | ATP4B | P51164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31458896 | 0.78 | CYP11B1 (0.46) | CSNK2A1CYP11B1CYP11B2 | |
| SCHEMBL17785010 | 0.78 | CYP11B1 (0.41) | CYP11B1CYP11B2FLT3KDM4ETDP1 | |
| SCHEMBL25826341 | 0.78 | CYP11B1 (0.41) | CYP11B1CYP11B2FLT3KDM4ETDP1 | |
| SCHEMBL28400087 | 0.78 | CYP11B1 (0.46) | CSNK2A1CYP11B1CYP11B2 | |
| SCHEMBL1924124 | 0.77 | FLT3 (0.37) | CSNK2A1FLT3HTTKDM4E | |
| SCHEMBL16421188 | 0.76 | PARP1 (0.33) | CYP11B1CYP11B2HTTKDM4E | |
| SCHEMBL335179 | 0.75 | HSD17B10 (0.37) | KDM4E | |
| SCHEMBL25826351 | 0.74 | AR (0.35) | CYP11B1CYP11B2HTTKDM4E | |
| SCHEMBL22622053 | 0.73 | GAA (0.32) | — | |
| SCHEMBL12042082 | 0.72 | KDM4E (0.40) | CYP11B1CYP11B2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289732-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | NOVARTIS AG (CH) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289732-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | WDR5, WDR77, WDR1 | CSNK2A1 559/4885CYP11B1 4074/4885CYP11B2 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.